L. Stamatatos

CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals

This study shows that CD4bs immunogens can elicit potent, broad anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals.

Adjuvants influence the maturation of VRC01-like antibodies during immunization

The study examines how three adjuvants affect the mutation patterns and antibody titers of VRC01-class BCRs during immunization with specific immunogens.

An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice

Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

The paper identifies an antibody from a clinical trial that binds a different HIV-1 Env domain than VRC01-class antibodies and shows that epitope switching requires specific CDR changes.

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit.

This paper identifies a conserved neutralizing epitope on the spike S2 subunit of sarbecoviruses, demonstrating cross-neutralization against multiple variants and a bat coronavirus.

Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects

The paper isolates and characterizes cross-neutralizing antibodies from COVID-19 patients, identifying antibodies that neutralize both SARS-CoV-1 and SARS-CoV-2, including variants.

Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy

This study uses live imaging to show that neutralizing antibodies against SARS-CoV-2 need both Fab and Fc functions to effectively prevent and resolve infection in mice.

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.

Designed proteins assemble antibodies into modular nanocages

The paper designs modular nanocages that assemble antibodies into precise geometries, enhancing signaling and neutralization compared to free antibodies.

Antibody binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

The paper determines the X-ray crystal structure of a potent SARS-CoV-2 neutralizing antibody, CV30, in complex with the RBD, showing its epitope overlaps with ACE2 binding site.

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

This study characterizes neutralizing antibodies from a SARS-CoV-2 infected individual, finding that most antibodies are non-neutralizing and target epitopes outside the RBD, while two potent neutralizers bind the RBD with minimal mutation.

Antigen-specific humoral immune responses by CRISPR/Cas9-edited B cells

CRISPR/Cas9-edited B cells produce broadly neutralizing antibodies against HIV-1 and elicit protective immune responses in vivo.

Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen binding affinity

This study investigates how B cell precursor frequency and antigen binding affinity influence germinal center recruitment and clonal expansion in HIV-1 vaccine development using adoptive transfer experiments.